Ghrelin: A link between ageing, metabolism and neurodegenerative disorders

Neurobiology of Disease

Volumn 72, Issue Part A, 2014, Pages 72-83

  Stoyanova, I I ^a  

^a UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Ageing; Ghrelin; Metabolism; Neurodegenerative diseases; Neuroprotection

Indexed keywords

AMYLOID BETA PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; GHRELIN; HUNTINGTIN; NEUROPEPTIDE Y; NEUROPROTECTIVE AGENT;

AGING; ALZHEIMER DISEASE; DAYTIME SOMNOLENCE; DEGENERATIVE DISEASE; ENERGY METABOLISM; GASTROINTESTINAL TRACT FUNCTION; GLUCOSE METABOLISM; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HUNTINGTON CHOREA; INSOMNIA; LEARNING; LEWY BODY; LIPID METABOLISM; MEMORY CONSOLIDATION; METABOLISM; MITOCHONDRIAL RESPIRATION; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARASOMNIA; PARKINSON DISEASE; REVIEW; SHORT TERM MEMORY; SLEEP WAKING CYCLE; WEIGHT REDUCTION; ANIMAL; BRAIN; HUNTINGTON DISEASE; MEMORY; NEURODEGENERATIVE DISEASES; PHYSIOLOGY; SECRETION (PROCESS); SLEEP;

AGING; ALZHEIMER DISEASE; ANIMALS; BRAIN; ENERGY METABOLISM; GHRELIN; HUMANS; HUNTINGTON DISEASE; MEMORY; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SLEEP;

EID: 84909643164     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.08.026     Document Type: Review

References (273)

1. Aarsland D., Andersen K., Larsen J.P., Lolk A., Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol. 2003, 60(3):387-392. (PubMed PMID: 12633150).
2. Abizaid A., Liu Z.W., Andrews Z.B., Shanabrough M., Borok E., Elsworth J.D., et al. Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J. Clin. Invest. 2006, 116(12):3229-3239.
3. Andersson U., Filipsson K., Abbott C.R., Woods A., Smith K., Bloom S.R., et al. AMP-activated protein kinase plays a role in the control of food intake. J. Biol. Chem. 2004, 279(13):12005-12008.
4. Andrew S.E., Goldberg Y.P., Kremer B., Telenius H., Theilmann J., Adam S., et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet. 1993, 4(4):398-403.
5. Andrews Z.B. Central mechanisms involved in the orexigenic actions of ghrelin. Peptides 2011, 32(11):2248-2255.
6. Andrews Z.B., Horvath B., Barnstable C.J., Elsworth J., Yang L., Beal M.F., et al. Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease. J. Neurosci. 2005, 25(1):184-191.
7. Andrews Z.B., Liu Z.W., Walllingford N., Erion D.M., Borok E., Friedman J.M., et al. UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. Nature 2008, 454(7206):846-851.
8. Andrews Z.B., Erion D., Beiler R., Liu Z.W., Abizaid A., Zigman J., et al. Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism. J. Neurosci. 2009, 29(45):14057-14065.
9. Angeles-Castellanos M., Aguilar-Roblero R., Escobar C. c-Fos expression in hypothalamic nuclei of food-entrained rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 286(1):R158-R165.
10. Ariyasu H., Takaya K., Tagami T., Ogawa Y., Hosoda K., Akamizu T., et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J. Clin. Endocrinol. Metab. 2001, 86(10):4753-4758.
11. Asakawa A., Inui A., Fujimiya M., Sakamaki R., Shinfuku N., Ueta Y., et al. Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 2005, 54(1):18-24.
12. Atcha Z., Chen W.S., Ong A.B., Wong F.K., Neo A., Browne E.R., et al. Cognitive enhancing effects of ghrelin receptor agonists. Psychopharmacology (Berlin) 2009, 206(3):415-427.
13. Autry A.E., Monteggia L.M. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol. Rev. 2012, 64(2):238-258.
14. Aziz N.A., Swaab D.F., Pijl H., Roos R.A. Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. Rev. Neurosci. 2007, 18(3-4):223-251.
15. Aziz A., Fronczek R., Maat-Schieman M., Unmehopa U., Roelandse F., Overeem S., et al. Hypocretin and melanin-concentrating hormone in patients with Huntington disease. Brain Pathol. 2008, 18(4):474-483.
16. Aziz N.A., van der Marck M.A., Pijl H., Olde Rikkert M.G., Bloem B.R., Roos R.A. Weight loss in neurodegenerative disorders. J. Neurol. 2008, 255(12):1872-1880.
17. Aziz N.A., Anguelova G.V., Marinus J., Lammers G.J., Roos R.A. Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease. Parkinsonism Relat. Disord. 2010, 16(5):345-350.
18. Aziz N.A., Pijl H., Frölich M., Schröder-van der Elst J.P., Van der Bent C., Roelfsema F., et al. Growth hormone and ghrelin secretion are associated with clinical severity in Huntington's disease. Eur. J. Neurol. 2010, 17(2):280-288.
19. Banks P.J., Warburton E.C., Brown M.W., Bashir Z.I. Mechanisms of synaptic plasticity and recognition memory in the perirhinal cortex. Prog. Mol. Biol. Transl. Sci. 2014, 122:193-209.
20. Baquet Z.C., Bickford P.C., Jones K.R. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J. Neurosci. 2005, 25(26):6251-6259.
21. Barazzoni R., Zanetti M., Ferreira C., Vinci P., Pirulli A., Mucci M., et al. Relationships between desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome. J. Clin. Endocrinol. Metab. 2007, 92:3935-3940.
22. Barde Y.A., Edgar D., Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J. 1982, 1(5):549-553.
23. Bates G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 2003, 361(9369):1642-1644.
24. Bayliss J.A., Andrews Z.B. Ghrelin is neuroprotective in Parkinson's disease: molecular mechanisms of metabolic neuroprotection. Ther. Adv. Endocrinol. Metab. 2013, 4(1):25-36.
25. Beach T.G., Adler C.H., Sue L.I., Vedders L., Lue L., White Iii C.L., et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010, 119(6):689-702.
26. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986, 321(6066):168-171.
27. Benso A., St-Pierre D., Prodam F., Gramaglia E., Granata R., Van der Lely A.J., et al. Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans. Eur. J. Endocrinol. 2012, 166:911-916.
28. Berrout L., Isokawa M. Ghrelin promotes reorganization of dendritic spines in cultured rat hippocampal slices. Neurosci. Lett. 2012, 516(2):280-284.
29. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3(12):1301-1306.
30. Bodosi B., Gardi J., Hajdu I., Szentirmai E., Obal F., Krueger J.M. Rhythms of ghrelin, leptin, and sleep in rats: effects of the normal diurnal cycle, restricted feeding, and sleep deprivation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 287(5):R1071-R1079.
31. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82(4):239-259.
32. Braak H., Ghebremedhin E., Rüb U., Bratzke H., Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004, 318(1):121-134.
33. Broglio F., Gottero C., Benso A., Prodam F., Casanueva F.F., Dieguez C., et al. Acetylcholine does not play a major role in mediating the endocrine responses to ghrelin, a natural ligand of the GH secretagogue receptor, in humans. Clin Endocrinol (Oxf) 2003, 58(1):92-98.
34. Broglio F., Gottero C., Prodam F., Gauna C., Muccioli G., Papotti M., et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J. Clin. Endocrinol. Metab. 2004, 89:3062-3065.
35. Brouillet E., Hantraye P., Ferrante R.J., Dolan R., Leroy-Willig A., Kowall N.W., et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl. Acad. Sci. U. S. A. 1995, 92(15):7105-7109.
36. Burdyga G., Lal S., Spiller D., Jiang W., Thompson D.G., Attwood S., et al. Localization of orexin-1 receptors to vagal afferent neurons in the rat and humans. Gastroenterology 2003, 124:129-139.
37. Cai H., Cong W.N., Ji S., Rothman S., Maudsley S., Martin B. Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. Curr. Alzheimer Res. 2012, 9(1):5-17.
38. Camiña J.P., Carreira M.C., Micic D., Pombo M., Kelestimur F., Dieguez C., et al. Regulation of ghrelin secretion and action. Endocrine 2003, 22(1):5-12.
39. Canals J.M., Pineda J.R., Torres-Peraza J.F., Bosch M., Martín-Ibañez R., Muñoz M.T., et al. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 2004, 24(35):7727-7739.
40. Candela S., Giubilei F., Orzi F. Heterogeneous pathologies associated with dementia in Parkinsonism share a prion-like spreading mechanism. Arch. Ital. Biol. Dec 2013, 151(4):169-178.
41. Cardinal R.N., Parkinson J.A., Hall J., Everitt B.J. Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. Neurosci. Biobehav. Rev. 2002, 26(3):321-352.
42. Carlini V.P., Monzón M.E., Varas M.M., Cragnolini A.B., Schiöth H.B., Scimonelli T.N., de Barioglio S.R. Ghrelin increases anxiety-like behavior and memory retention in rats. Biochem. Biophys. Res. Commun. 2002, 299(5):739-743.
43. Carlini V.P., Varas M.M., Cragnolini A.B., Schiöth H.B., Scimonelli T.N., de Barioglio S.R. Differential role of the hippocampus, amygdala, and dorsal raphe nucleus in regulating feeding, memory, and anxiety-like behavioral responses to ghrelin. Biochem. Biophys. Res. Commun. 2004, 313(3):635-641.
44. Carlini V.P., Gaydou R.C., Schiöth H.B., de Barioglio S.R. Selective serotonin reuptake inhibitor (fluoxetine) decreases the effects of ghrelin on memory retention and food intake. Regul. Pept. 2007, 140(1-2):65-73.
45. Carlini V.P., Martini A.C., Schiöth H.B., Ruiz R.D., Fiol de Cuneo M., de Barioglio S.R. Decreased memory for novel object recognition in chronically food-restricted mice is reversed by acute ghrelin administration. Neuroscience 2008, 153(4):929-934.
46. Carlini V.P., Perez M.F., Salde E., Schiöth H.B., Ramirez O.A., de Barioglio S.R. Ghrelin induced memory facilitation implicates nitric oxide synthase activation and decrease in the threshold to promote LTP in hippocampal dentate gyrus. Physiol. Behav. 2010, 101(1):117-123.
47. Castañeda T.R., Tong J., Datta R., Culler M., Tschöp M.H. Ghrelin in the regulation of body weight and metabolism. Front. Neuroendocrinol. 2010, 31(1):44-60.
48. Cattaneo E., Rigamonti D., Goffredo D., Zuccato C., Squitieri F., Sipione S. Loss of normal huntingtin function: new developments in Huntington's disease research. Trends Neurosci. 2001, 24(3):182-188.
49. Chan P.H. Mitochondria and neuronal death/survival signaling pathways in cerebral ischemia. Neurochem. Res. 2004, 29(11):1943-1949.
50. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., Hobbs W., Vonsattel J.P., Cha J.H., Friedlander R.M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000, 6(7):797-801.
51. Chen L., Xing T., Wang M., Miao Y., Tang M., Chen J., Li G., et al. Local infusion of ghrelin enhanced hippocampal synaptic plasticity and spatial memory through activation of phosphoinositide 3-kinase in the dentate gyrus of adult rats. Eur. J. Neurosci. 2011, 33(2):266-275.
52. Cheng B., Mattson M.P. NT-3 and BDNF protect CNS neurons against metabolic/excitotoxic insults. Brain Res. 1994, 640(1-2):56-67.
53. Chung H., Kim E., Lee D.H., Seo S., Ju S., Lee D., Kim H., Park S. Ghrelin inhibits apoptosis in hypothalamic neuronal cells during oxygen-glucose deprivation. Endocrinology 2007, 148(1):148-159.
54. Cowley M.A., Smith R.G., Diano S., Tschöp M., Pronchuk N., Grove K.L., et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003, 37(4):649-661.
55. Creyghton W.M., van Dam P.S., Koppeschaar H.P. The role of the somatotropic system in cognition and other cerebral functions. Semin. Vasc. Med. 2004, 4(2):167-172.
56. Cummings D.E., Purnell J.Q., Frayo R.S., Schmidova K., Wisse B.E., Weigle D.S. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001, 50(8):1714-1719.
57. Date Y. Ghrelin and the vagus nerve. Methods in Enzymology 2012, 514:261-269. Academic Press, Burlington. M. Kojima, K. Kangawa (Eds.).
58. Date Y., Kojima M., Hosoda H., Sawaguchi A., Mondal M.S., Suganuma T., Matsukura S., et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 2000, 141(11):4255-4261.
59. Date Y., Nakazato M., Murakami N., Kojima M., Kangawa K., Matsukura S. Ghrelin acts in the central nervous system to stimulate gastric acid secretion. Biochem. Biophys. Res. Commun. 2001, 280(3):904-907.
60. Date Y., Murakami N., Toshinai K., Matsukura S., Niijima A., Matsuo H., Kangawa K., Nakazato M. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 2002, 123:1120-1128.
61. Date Y., Nakazato M., Hashiguchi S., Dezaki K., Mondal M.S., Hosoda H., et al. Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. Diabetes 2002, 51(1):124-129.
62. Davison J.S. Activation of vagal gastric mechanoreceptors by cholecystokinin. Proc. West. Pharmacol. Soc. 1986, 29:363-366.
63. Delhanty P.J., van der Lely A.J. Ghrelin and glucose homeostasis. Peptides 2011, 32(11):2309-2318.
64. Delhanty P.J., Sun Y., Visser J.A., van Kerkwijk A., Huisman M., van Ijcken W.F., et al. Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice. PLoS One 2010, 5:e11749.
65. Delhanty P.J., Neggers S.J., Van der Lely A.J. Mechanisms in endocrinology: ghrelin: the differences between acyl- and des-acyl ghrelin. Eur. J. Endocrinol. 2012, 167(5):601-608.
66. Delhanty P.J., Neggers S.J., van der Lely A.J. Should we consider des-acyl ghrelin as a separate hormone and if so, what does it do?. Front. Horm. Res. 2014, 42:163-174.
67. Diano S., Farr S.A., Benoit S.C., McNay E.C., da Silva I., Horvath B., et al. Ghrelin controls hippocampal spine synapse density and memory performance. Nat. Neurosci. 2006, 9(3):381-388.
68. Djoussé L., Knowlton B., Cupples L.A., Marder K., Shoulson I., Myers R.H. Weight loss in early stage of Huntington's disease. Neurology 2002, 59(9):1325-1330.
69. Dockray G.J. Immunochemical evidence of cholecystokinin-like peptides in brain. Nature 1976, 264:568-570.
70. Dockray G.J. Regulatory peptides and the neuroendocrinology of gut-brain relations. Q. J. Exp. Physiol. 1988, 73:703-727.
71. Dockray G.J. Gastrointestinal hormones and the dialogue between gut and brain. J. Physiol. Mar 17 2014, 10.1113/jphysiol.2014.270850.
72. Duan W., Guo Z., Jiang H., Ladenheim B., Xu X., Cadet J.L., Mattson M.P. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann. Neurol. 2004, 55(4):590-594.
73. Dzaja A., Dalal M.A., Himmerich H., Uhr M., Pollmächer T., Schuld A. Sleep enhances nocturnal plasma ghrelin levels in healthy subjects. Am. J. Physiol. Endocrinol. Metab. 2004, 286(6):E963-E967.
74. Evers E.A., Tillie D.E., van der Veen F.M., Lieben C.K., Jolles J., Deutz N.E., et al. Effects of a novel method of acute tryptophan depletion on plasma tryptophan and cognitive performance in healthy volunteers. Psychopharmacology (Berlin) 2005, 178(1):92-99.
75. Evidente V.G., Caviness J.N., Adler C.H., Gwinn-Hardy K.A., Pratley R.E. Serum leptin concentrations and satiety in Parkinson's disease patients with and without weight loss. Mov. Disord. 2001, 16(5):924-927.
76. Fanselow M.S., Dong H.W. Are the dorsal and ventral hippocampus functionally distinct structures?. Neuron 2010, 65(1):7-19.
77. Farrer L.A., Yu P.L. Anthropometric discrimination among affected, at-risk, and not-at-risk individuals in families with Huntington disease. Am. J. Med. Genet. Jun 1985, 21(2):307-316.
78. Feldman M., Richardson C.T. Role of thought, sight, smell, and taste of food in the cephalic phase of gastric acid secretion in humans. Gastroenterology 1986, 90(2):428-433.
79. Ferrer I., Goutan E., Marín C., Rey M.J., Ribalta T. Brain-derived neurotrophic factor in Huntington disease. Brain Res. 2000, 866(1-2):257-261.
80. Figlewicz D.P., Brot M.D., McCall A.L., Szot P. Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: a molecular study. Brain Res. 1996, 736(1-2):54-60.
81. Figlewicz D.P., Evans S.B., Murphy J., Hoen M., Baskin D.G. Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat. Brain Res. 2003, 964(1):107-115.
82. Figurov A., Pozzo-Miller L.D., Olafsson P., Wang T., Lu B. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 1996, 381(6584):706-709.
83. Fiszer U., Michałowska M., Baranowska B., Wolińska-Witort E., Jeske W., Jethon M., et al. Leptin and ghrelin concentrations and weight loss in Parkinson's disease. Acta Neurol. Scand. 2010, 121(4):230-236.
84. Fontán-Lozano A., Sáez-Cassanelli J.L., Inda M.C., de los Santos-Arteaga M., Sierra-Domínguez S.A., López-Lluch G., et al. Caloric restriction increases learning consolidation and facilitates synaptic plasticity through mechanisms dependent on NR2B subunits of the NMDA receptor. J. Neurosci. 2007, 27(38):10185-10195.
85. Freeman A., Ciliax B., Bakay R., Daley J., Miller R.D., Keating G., Levey A., Rye D. Nigrostriatal collaterals to thalamus degenerate in parkinsonian animal models. Ann. Neurol. 2001, 50:321-329.
86. Fry M., Ferguson A.V. Ghrelin: central nervous system sites of action in regulation of energy balance. Int. J. Pept. 2010, 2010. (pii 616757).
87. Gahete M.D., Rubio A., Córdoba-Chacón J., Gracia-Navarro F., Kineman R.D., Avila J., et al. Expression of the ghrelin and neurotensin systems is altered in the temporal lobe of Alzheimer's disease patients. J. Alzheimers Dis. 2010, 22(3):819-828.
88. Gahete M.D., Rincón-Fernández D., Villa-Osaba A., Hormaechea-Agulla D., Ibáñez-Costa A., Martínez-Fuentes A.J., et al. Ghrelin gene products, receptors, and GOAT enzyme: biological and pathophysiological insight. J. Endocrinol. 2014, 220(1):R1-R24.
89. Gaskin F.S., Farr S.A., Banks W.A., Kumar V.B., Morley J.E. Ghrelin-induced feeding is dependent on nitric oxide. Peptides. 2003, 24(6):913-918.
90. Gauna C., Meyler F.M., Janssen J.A., Delhanty P.J., Abribat T., Van Koetsveld P., et al. Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity. J. Clin. Endocrinol. Metab. 2004, 89(10):5035-5042.
91. Gauna C., Delhanty P.J., van Aken M.O., Janssen J.A., Themmen A.P., Hofland L.J., et al. Unacylated ghrelin is active on the INS-1E rat insulinoma cell line independently of the growth hormone secretagogue receptor type 1a and the corticotropin releasing factor 2 receptor. Mol. Cell. Endocrinol. 2006, 251:103-111.
92. Ghersi M.S., Casas S.M., Escudero C., Carlini V.P., Buteler F., Cabrera R.J., et al. Ghrelin inhibited serotonin release from hippocampal slices. Peptides 2011, 32(11):2367-2371.
93. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290(5493):985-989.
94. Giordano V., Peluso G., Iannuccelli M., Benatti P., Nicolai R., Calvani M. Systemic and brain metabolic dysfunction as a new paradigm for approaching Alzheimer's dementia. Neurochem. Res. 2007, 32(4-5):555-567.
95. Gispen W.H., Biessels G.J. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci. 2000, 23(11):542-549.
96. Goldman S.M., Tanner C. Etiology of Parkinson's disease. Parkinson's Disease and Movement Disorder 1998, 1333-1358. Williams and Wilkins, Baltimore. J. Jankovic, E. Tolosa (Eds.).
97. Gomes S., Martins I., Fonseca A.C., Oliveira C.R., Resende R., Pereira C.M. Protective effect of leptin and ghrelin against toxicity induced by amyloid-β oligomers in a hypothalamic cell line. J. Neuroendocrinol. 2014, 26(3):176-185.
98. Gomez R., Navarro M., Ferrer B., Trigo J.M., Bilbao A., Del A.I., et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J. Neurosci. 2002, 22:9612-9617.
99. Gomez-Pinilla F., Vaynman S., Ying Z. Brain-derived neurotrophic factor functions as a metabotrophin to mediate the effects of exercise on cognition. Eur. J. Neurosci. 2008, 28(11):2278-2287.
100. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Richardson R.J. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998, 50(5):1346-1350.
101. Granata R., Volante M., Settanni F., Gauna C., Ghé C., Annunziata M., et al. Unacylated ghrelin and obestatin increase islet cell mass and prevent diabetes in streptozotocin-treated newborn rats. J. Mol. Endocrinol. 2010, 45(1):9-17.
102. Green D.R., Reed J.C. Mitochondria and apoptosis. Science 1998, 281(5381):1309-1312.
103. Gruart A., Muñoz M.D., Delgado-García J.M. Involvement of the CA3-CA1 synapse in the acquisition of associative learning in behaving mice. J. Neurosci. 2006, 26(4):1077-1087.
104. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 1996, 39(3):385-389.
105. Guan X.M., Hess J.F., Yu H., Hey P.J., Van der Ploeg L.H. Differential expression of mRNA for leptin receptor isoforms in the rat brain. Mol. Cell. Endocrinol. 1997, 133(1):1-7.
106. Gunter T.E., Pfeiffer D.R. Mechanisms by which mitochondria transport calcium. Am. J. Physiol. 1990, 258(5 Pt 1):C755-C786.
107. Hagan J.J., Leslie R.A., Patel S., Evans M.L., Wattam T.A., Holmes S., et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(19):10911-10916.
108. Hahn T.M., Breininger J.F., Baskin D.G., Schwartz M.W. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat. Neurosci. 1998, 1(4):271-272.
109. Haider S., Khaliq S., Ahmed S.P., Haleem D.J. Long-term tryptophan administration enhances cognitive performance and increases 5HT metabolism in the hippocampus of female rats. Amino Acids 2006, 31(4):421-425.
110. Hansson C., Alvarez-Crespo M., Taube M., Skibicka K.P., Schmidt L., Karlsson-Lindahl L., et al. Influence of ghrelin on the central serotonergic signaling system in mice. Neuropharmacology 2014, 79:498-505.
111. Hardy J., Duff K., Hardy K.G., Perez-Tur J., Hutton M. Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat. Neurosci. 1998, 1(5):355-358.
112. Hasue R.H., Shammah-Lagnado S.J. Origin of the dopaminergic innervation of the central extended amygdala and accumbens shell: a combined retrograde tracing and immunohistochemical study in the rat. J. Comp. Neurol. 2002, 454(1):15-33.
113. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 2003, 60(8):1119-1122.
114. Hewson A.K., Dickson S.L. Systemic administration of ghrelin induces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed rats. J. Neuroendocrinol. 2000, 12(11):1047-1049.
115. Horowitz M.P., Greenamyre J.T. Gene-environment interactions in Parkinson's disease: the importance of animal modeling. Clin. Pharmacol. Ther. 2010, 88(4):467-474.
116. Horvath T.L. Suprachiasmatic efferents avoid phenestrated capillaries but innervate neuroendocrine cells, including those producing dopamine. Endocrinology 1997, 138(3):1312-1320.
117. Horvath T.L. An alternate pathway for visual signal integration into the hypothalamo-pituitary axis: retinorecipient intergeniculate neurons project to various regions of the hypothalamus and innervate neuroendocrine cells including those producing dopamine. J. Neurosci. 1998, 18(4):1546-1558.
118. Hosoda H., Kojima M., Matsuo H., Kangawa K. Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem. Biophys. Res. Commun. 2000, 279(3):909-913.
119. Hou Z., Miao Y., Gao L., Pan H., Zhu S. Ghrelin-containing neuron in cerebral cortex and hypothalamus linked with the DVC of brainstem in rat. Regul. Pept. 2006, 134(2-3):126-131.
120. Hoyer S. The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J. Neural Transm. 2002, 109(3):341-360.
121. Hroudová J., Singh N., Fišar Z. Mitochondrial dysfunctions in neurodegenerative diseases: relevance to Alzheimer's disease. Biomed Res. Int. 2014, 2014:175062.
122. Hsu L.J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., et al. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 2000, 157(2):401-410.
123. Hyman C., Hofer M., Barde Y.A., Juhasz M., Yancopoulos G.D., Squinto S.P., et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991, 350(6315):230-232.
124. Inhoff T., Mönnikes H., Noetzel S., Stengel A., Goebel M., Dinh Q.T., et al. Desacyl ghrelin inhibits the orexigenic effect of peripherally injected ghrelin in rats. Peptides 2008, 29(12):2159-2168.
125. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12(2):207-216.
126. Kanoski S.E., Fortin S.M., Ricks K.M., Grill H.J. Ghrelin signaling in the ventral hippocampus stimulates learned and motivational aspects of feeding via PI3K-Akt signaling. Biol. Psychiatry 2013, 73(9):915-923.
127. Kim Y.K., Yoon I.Y., Kim J.M., Jeong S.H., Kim K.W., Shin Y.K., et al. The implication of nigrostriatal dopaminergic degeneration in the pathogenesis of REM sleep behavior disorder. Eur. J. Neurol. 2010, 17(3):487-492.
128. Kluge M., Schussler P., Zuber V., Yassouridis A., Steiger A. Ghrelin administered in the early morning increases secretion of cortisol and growth hormone without affecting sleep. Psychoneuroendocrinology 2007, 32:287-292.
129. Kluge M., Schüssler P., Zuber V., Kleyer S., Yassouridis A., Dresler M., et al. Ghrelin enhances the nocturnal secretion of cortisol and growth hormone in young females without influencing sleep. Psychoneuroendocrinology 2007, 32:1079-1085.
130. Kluge M., Gazea M., Schüssler P., Genzel L., Dresler M., Kleyer S., et al. Ghrelin increases slow wave sleep and stage 2 sleep and decreases stage 1 sleep and REM sleep in elderly men but does not affect sleep in elderly women. Psychoneuroendocrinology 2010, 35(2):297-304.
131. Kojima M., Hosada H., Date Y., Nakazato M., Matsuo H., Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402:656-660.
132. Kremer H.P., Roos R.A. Weight loss in Huntington's disease. Arch. Neurol. Apr 1992, 4:349.
133. Kumar R., Salehi A., Rehfeld J.F., Hoglund P., Lindstrom E., Hakanson R. Proghrelin peptides: desacyl ghrelin is a powerful inhibitor of acylated ghrelin, likely to impair physiological effects of acyl ghrelin but not of obestatin A study of pancreatic polypeptide secretion from mouse islets. Regul. Pept. 2010, 164:65-70.
134. Kushnareva Y., Murphy A.N., Andreyev A. Complex I-mediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation-reduction state. Biochem. J. 2002, 368(Pt 2):545-553.
135. Lamont E.W., Bruton J., Blum I.D., Abizaid A. Ghrelin receptor-knockout mice display alterations in circadian rhythms of activity and feeding under constant lighting conditions. Eur. J. Neurosci. 2014, 39(2):207-217.
136. Landles C., Bates G.P. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep. 2004, 5(10):958-963.
137. Leak R.K., Moore R.Y. Topographic organization of suprachiasmatic nucleus projection neurons. J. Comp. Neurol. 2001, 433(3):312-334.
138. Lee J., Duan W., Mattson M.P. Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J. Neurochem. 2002, 82:1367-1375.
139. Lee H.M., Wang G., Englander E.W., Kojima M., Greeley G.H. Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations. Endocrinology 2002, 143(1):185-190.
140. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373(9680):2055-2066.
141. Lefterov I., Fitz N.F., Cronican A., Lefterov P., Staufenbiel M., Koldamova R. Memory deficits in APP23/Abca1+/- mice correlate with the level of Aβ oligomers. ASN Neuro Apr 30 2009, 1(2). (pii: e00006). 10.1042/AN20090015.
142. Leverenz J.B., Quinn J.F., Zabetian C., Zhang J., Montine K.S., Montine T.J. Cognitive impairment and dementia in patients with Parkinson disease. Curr. Top. Med. Chem. 2009, 9(10):903-912.
143. Levi S., Cox M., Lugon M., Hodkinson M., Tomkins A. Increased energy expenditure in Parkinson's disease. BMJ 1990, 301(6763):1256-1257.
144. Levine E.S., Crozier R.A., Black I.B., Plummer M.R. Brain-derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N-methyl-d-aspartic acid receptor activity. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(17):10235-10239.
145. Levivier M., Przedborski S., Bencsics C., Kang U.J. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J. Neurosci. 1995, 15(12):7810-7820.
146. Lewis B.L., O'Donnell P. Ventral tegmental area afferents to the prefrontal cortex maintain membrane potential 'up' states in pyramidal neurons via D(1) dopamine receptors. Cereb. Cortex 2000, 10(12):1168-1175.
147. Lieberman A. Are dementia and depression in Parkinson's disease related?. J. Neurol. Sci. Oct 25 2006, 248(1-2):138-142.
148. Lipman I.J., Boykin M.E., Flora R.E. Glucose intolerance in Parkinson's disease. J. Chronic Dis. 1974, 27(11-12):573-579.
149. Liu J., Prudom C.E., Nass R., Pezzoli S.S., Oliveri M.C., Johnson M.L., et al. Novel ghrelin assays provide evidence for independent regulation of ghrelin acylation and secretion in healthy young men. J. Clin. Endocrinol. Metab. 2008, 93(5):1980-1987.
150. Lloyd K.C.K., Debas H.T. Peripheral regulation of gastric acid secretion. Physiology of the Gastrointestinal Tract 1994, 1185-1226. Raven Press, New York. L.R. Johnson (Ed.).
151. López M., Lage R., Saha A.K., Pérez-Tilve D., Vázquez M.J., Varela L., et al. Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab. 2008, 7:389-399.
152. Lu J., Jhou T.C., Saper C.B. Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J. Neurosci. 2006, 26(1):193-202.
153. Lucidi P., Murdolo G., Di Loreto C., Parlanti N., De Cicco A., Ranchelli A., et al. Meal intake similarly reduces circulating concentrations of octanoyl and total ghrelin in humans. J. Endocrinol. Invest. 2004, 27(5):RC12-RC15.
154. Lynch G., Kramar E.A., Rex C.S., Jia Y., Chappas D., Gall C.M., et al. Brainderived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease. J. Neurosci. 2007, 27:4424-4434.
155. Ma L.Y., Zhang D.M., Tang Y., Lu Y., Zhang Y., Gao Y., et al. Ghrelin-attenuated cognitive dysfunction in streptozotocin-induced diabetic rats. Alzheimer Dis. Assoc. Disord. 2011, 25(4):352-363.
156. Malik S., McGlone F., Bedrossian D., Dagher A. Ghrelin modulates brain activity in areas that control appetitive behavior. Cell Metab. 2008, 7(5):400-409.
157. Marrinan S., Emmanuel A.V., Burn D.J. Delayed gastric emptying in Parkinson's disease. Mov. Disord. 2014, 29(1):23-32.
158. Martens K., Bottelbergs A., Baes M. Ectopic recombination in the central and peripheral nervous system by aP2/FABP4-Cre mice: implications for metabolism research. FEBS Lett. 2010, 584:1054-1058.
159. Martin J.B. Molecular basis of the neurodegenerative disorders. N. Engl. J. Med. 1999, 340(25):1970-1980.
160. Martin L.J. Neuronal cell death in nervous system development, disease, and injury (Review). Int J Mol Med. 2001, 7(5):455-478.
161. Martinez T.N., Greenamyre J.T. Toxin models of mitochondrial dysfunction in Parkinson's disease. Antioxid. Redox Signal. 2012, 16(9):920-934.
162. Masuda Y., Tanaka T., Inomata N., Ohnuma N., Tanaka S., Itoh Z., et al. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem. Biophys. Res. Commun. 2000, 276(3):905-908.
163. Maswood N., Young J., Tilmont E., Zhang Z., Gash D.M., Gerhardt G.A., et al. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(52):18171-18176.
164. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature. 2004, 430(7000):631-639.
165. Mattson M.P., Maudsley S., Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 2004, 27(10):589-594.
166. Mattson M.P. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci. 2008, 1144:97-112.
167. Mattson M.P., Lovell M.A., Furukawa K., Markesbery W.R. Neurotrophic factors attenuate glutamate-induced accumulation of peroxides, elevation of intracellular Ca2+ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons. J. Neurochem. 1995, 65(4):1740-1751.
168. Modugno N., Lena F., Di Biasio F., Cerrone G., Ruggieri S., Fornai F. A clinical overview of non-motor symptoms in Parkinson's Disease. Arch. Ital. Biol. 2013, 151(4):148-168.
169. Moon M., Kim H.G., Hwang L., Seo J.H., Kim S., Hwang S., et al. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation. Neurotox. Res. 2009, 15(4):332-347.
170. Moon M., Choi J.G., Nam D.W., Hong H.S., Choi Y.J., Oh M.S., et al. Ghrelin ameliorates cognitive dysfunction and neurodegeneration in intrahippocampal amyloid-β-1-42 oligomer injected mice. J. Alzheimers Dis. 2011, 23:147-159.
171. Moon M., Cha M.Y., Mook-Jung I. Impaired hippocampal neurogenesis and its enhancement with ghrelin in 5XFAD mice. J. Alzheimers Dis. 2014, 41(1):233-241.
172. Morley J.E. Anorexia of aging: physiologic and pathologic. Am. J. Clin. Nutr. 1997, 66(4):760-773.
173. Moroz N., Tong M., Longato L., Xu H., de la Monte S.M. Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus. J. Alzheimers Dis. 2008, 15(1):29-44.
174. Morris J.K., Zhang H., Gupte A.A., Bomhoff G.L., Stanford J.A., Geiger P.C. Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease. Brain Res. 2008, 1240:185-195.
175. Muccioli G., Pons N., Ghè C., Catapano F., Granata R., Ghigo E. Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. Eur. J. Pharmacol. 2004, 498(1-3):27-35.
176. Müller E.E., Rolla M., Ghigo E., Belliti D., Arvat E., Andreoni A., et al. Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications. Drugs 1995, 50(5):805-837.
177. Muller A.F., Janssen J.A., Hofland L.J., Lamberts S.W., Bidlingmaier M., Strasburger C.J., et al. Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance. J. Clin. Endocrinol. Metab. 2001, 86(2):590-593.
178. Murer M.G., Yan Q., Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Prog. Neurobiol. 2001, 63(1):71-124.
179. Nagahara A.H., Merrill D.A., Coppola G., Tsukada S., Schroeder B.E., Shaked G.M., Wang L., Blesch A., Kim A., Conner J.M., Rockenstein E., Chao M.V., Koo E.H., Geschwind D., Masliah E., Chiba A.A., Tuszynski M.H. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med. 2009, 15(3):331-337.
180. Nakao N., Brundin P. Effects of alpha-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid. Neuroscience 1997, 76(3):749-761.
181. Natale G., Pasquali L., Ruggieri S., Paparelli A., Fornai F. Parkinson's disease and the gut: a well-known clinical association in need of an effective cure and explanation. Neurogastroenterol. Motil. 2008, 20(7):741-749.
182. Neary N.M., Small C.J., Wren A.M., Lee J.L., Druce M.R., Palmieri C., et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 2004, 89(6):2832-2836.
183. Ohta H., Yamazaki S., McMahon D.G. Constant light desynchronizes mammalian clock neurons. Nat. Neurosci. 2005, 8(3):267-269.
184. Oliff H.S., Berchtold N.C., Isackson P., Cotman C.W. Exercise-induced regulation of brain-derived neurotrophic factor (BDNF) transcripts in the rat hippocampus. Brain Res. Mol. Brain Res. 1998, 61(1-2):147-153.
185. Ona V.O., Li M., Vonsattel J.P., Andrews L.J., Khan S.Q., Chung W.M., et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999, 399(6733):263-267.
186. Ondo W.G. Sleep/wake problems in Parkinson's disease: pathophysiology and clinicopathologic correlations. J. Neural Transm. May 25 2014, 121(1):3-13.
187. Otto B., Cuntz U., Fruehauf E., Wawarta R., Folwaczny C., Riepl R.L., et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur. J. Endocrinol. 2001, 145(5):669-673.
188. Pacifico L., Poggiogalle E., Costantino F., Anania C., Ferraro F., Chiarelli F., et al. Acylated and nonacylated ghrelin levels and their associations with insulin resistance in obese and normal weight children with metabolic syndrome. Eur. J. Endocrinol. 2009, 161:861-870.
189. Pallier P.N., Maywood E.S., Zheng Z., Chesham J.E., Inyushkin A.N., Dyball R., et al. Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease. J. Neurosci. 2007, 27(29):7869-7878.
190. Patterson Z.R., Ducharme R., Anisman H., Abizaid A. Altered metabolic and neurochemical responses to chronic unpredictable stressors in ghrelin receptor-deficient mice. Eur. J. Neurosci. 2010, 32(4):632-639.
191. Petersén A., Björkqvist M. Hypothalamic-endocrine aspects in Huntington's disease. Eur. J. Neurosci. 2006, 24(4):961-967.
192. Petersén A., Castilho R.F., Hansson O., Wieloch T., Brundin P. Oxidative stress, mitochondrial permeability transition and activation of caspases in calcium ionophore A23187-induced death of cultured striatal neurons. Brain Res. 2000, 857(1-2):20-29.
193. Petkov V.D., Kehayov R. Effects of agonists and antagonists of some serotonin-receptor subtypes on memory and their modulation by the 5-HT-uptake inhibitor fluoxetine. Acta Physiol. Pharmacol. Bulg. 1994, 20(3-4):83-90.
194. Phillips H.S., Hains J.M., Armanini M., Laramee G.R., Johnson S.A., Winslow J.W. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 1991, 7(5):695-702.
195. Pinto S., Roseberry A.G., Liu H., Diano S., Shanabrough M., Cai X., et al. Rapid rewiring of arcuate nucleus feeding circuits by leptin. Science 2004, 304(5667):110-115.
196. Pitsikas N., Algeri S. Deterioration of spatial and nonspatial reference and working memory in aged rats: protective effect of life-long calorie restriction. Neurobiol. Aging 1992, 13(3):369-373.
197. Portera-Cailliau C., Hedreen J.C., Price D.L., Koliatsos V.E. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci. 1995, 15(5 Pt 2):3775-3787.
198. Postuma R.B., Bertrand J.A., Montplaisir J., Desjardins C., Vendette M., Rios Romenets S., Panisset M., Gagnon J.F. Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson's disease: a prospective study. Mov. Disord. 2012, 27(6):720-726.
199. Proto C., Romualdi D., Cento R.M., Spada R.S., Di Mento G., Ferri R., Lanzone A. Plasma levels of neuropeptides in Alzheimer's disease. Gynecol. Endocrinol. 2006, 22(4):213-218.
200. Ravussin E., Tschöp M., Morales S., Bouchard C., Heiman M.L. Plasma ghrelin concentration and energy balance: overfeeding and negative energy balance studies in twins. J. Clin. Endocrinol. Metab. 2001, 86(9):4547-4551.
201. Reynolds I.J., Hastings T.G. Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. J. Neurosci. 1995, 15(5 Pt 1):3318-3327.
202. Rigamonti A.E., Pincelli A.I., Corrà B., Viarengo R., Bonomo S.M., Galimberti D., et al. Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients. J. Endocrinol. 2002, 175(1):R1-R5.
203. Rodriguez A., Gomez-Ambrosi J., Catalan V., Gil M.J., Becerril S., Sainz N., et al. Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int. J. Obes. 2009, 33:541-552.
204. Rolls E.T. Neural processing related to feeding in primates. Appetite: Neural and Behavioral Bases 1994, 11-53. Oxford University Press, Oxford, UK. C.R. Legg, D.A. Booth (Eds.).
205. Romenets S.R., Gagnon J.F., Latreille V., Panniset M., Chouinard S., Montplaisir J., et al. Rapid eye movement sleep behavior disorder and subtypes of Parkinson's disease. Mov. Disord. 2012, 27(8):996-1003.
206. Rosenzweig E.S., Barnes C.A. Impact of aging on hippocampal function: plasticity, network dynamics, and cognition. Prog. Neurobiol. 2003, 69(3):143-179.
207. Rossi C., Angelucci A., Costantin L., Braschi C., Mazzantini M., Babbini F., et al. Brain-derived neurotrophic factor (BDNF) is required for the enhancement of hippocampal neurogenesis following environmental enrichment. Eur. J. Neurosci. 2006, 24(7):1850-1856.
208. Sakata I., Nakamura K., Yamazaki M., Matsubara M., Hayashi Y., Kangawa K., et al. Ghrelin-producing cells exist as two types of cells, closed- and opened-type cells, in the rat gastrointestinal tract. Peptides 2002, 23(3):531-536.
209. Sandyk R. The relationship between diabetes mellitus and Parkinson's disease. Int. J. Neurosci. 1993, 69(1-4):125-130. (Mar-Apr).
210. Saper C.B., Petito C.K. Correspondence of melanin-pigmented neurons in human brain with A1-A14 catecholamine cell groups. Brain 1982, 105(Pt 1):87-101.
211. Saper C.B., Chou T.C., Elmquist J.K. The need to feed: homeostatic and hedonic control of eating. Neuron 2002, 36:199-211.
212. Saper C.B., Scammell T.E., Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005, 437(7063):1257-1263.
213. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 1(8649):1269.
214. Schapira A.H., Olanow C.W., Greenamyre J.T., Bezard E. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet 2014 Aug 9, 384(9942):545-555.
215. Schenck C.H., Mahowald M.W. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16years after its formal identification in SLEEP. Sleep 2002, 25(2):120-138.
216. Schiavo-Cardozo D., Lima M.M., Pareja J.C., Geloneze B. Appetite-regulating hormones from the upper gut: disrupted control of xenin and ghrelin in night workers. Clin. Endocrinol. (Oxf) 2013, 79:807-811.
217. Schilling G., Sharp A.H., Loev S.J., Wagster M.V., Li S.H., Stine O.C., Ross C.A. Expression of the Huntington's disease (IT15) protein product in HD patients. Hum. Mol. Genet. 1995, 4(8):1365-1371.
218. Sendtner M., Pei G., Beck M., Schweizer U., Wiese S. Developmental motoneuron cell death and neurotrophic factors. Cell Tissue Res. 2000, 301(1):71-84.
219. Seoane L.M., Tovar S.A., Perez D., Mallo F., Lopez M., Señaris R., et al. Orexin A suppresses in vivo GH secretion. Eur. J. Endocrinol. 2004, 150(5):731-736.
220. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 2003, 23(34):10756-10764.
221. Sherer T.B., Kim J.H., Betarbet R., Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 2003, 179(1):9-16.
222. Sherer T.B., Richardson J.R., Testa C.M., Seo B.B., Panov A.V., Yagi T., et al. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J. Neurochem. 2007, 100(6):1469-1479.
223. Sherin J.E., Elmquist J.K., Torrealba F., Saper C.B. Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat. J. Neurosci. 1998, 18(12):4705-4721.
224. Shimada M., Date Y., Mondal M.S., Toshinai K., Shimbara T., Fukunaga K., et al. Somatostatin suppresses ghrelin secretion from the rat stomach. Biochem. Biophys. Res. Commun. 2003, 302(3):520-525.
225. Solomon A., De Fanti B.A., Martínez J.A. Peripheral ghrelin interacts with orexin neurons in glucostatic signalling. Regul. Pept. 2007, 144(1-3):17-24.
226. Spiegel K., Tasali E., Leproult R., Scherberg N., Van Cauter E. Twenty-four-hour profiles of acylated and total ghrelin: relationship with glucose levels and impact of time of day and sleep. J. Clin. Endocrinol. Metab. 2011, 96(2):486-493.
227. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388(6645):839-840.
228. Spires T.L., Grote H.E., Varshney N.K., Cordery P.M., van Dellen A., Blakemore C., et al. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J. Neurosci. 2004, 24(9):2270-2276.
229. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J. Alzheimers Dis. 2005, 7(1):63-80.
230. Steiger A. Ghrelin and sleep-wake regulation. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292(1):R573-R574.
231. Steiger A., Dresler M., Schüssler P., Kluge M. Ghrelin in mental health, sleep, memory. Mol. Cell. Endocrinol. 2011, 340(1):88-96.
232. Stoyanova I.I. Ghrelin: expression and functions in the central nervous system. Ghrelin: Production, Action Mechanisms and Physiological Effects 2012, 57-75. NOVA Science Publishers, Inc., New York. H. Yamada, K. Takahashi (Eds.).
233. Stoyanova I.I., le Feber J. Ghrelin accelerates synapse formation and activity development in cultured cortical networks. BMC Neurosci. 2014, 15:49.
234. Stoyanova I.I., Wiertz R.W., Rutten W.L. Time-dependent changes in ghrelin-immunoreactivity in dissociated neuronal cultures of the newborn rat neocortex. Regul. Pept. 2009, 158(1-3):86-90.
235. Stoyanova I.I., le Feber J., Rutten W.L. Ghrelin stimulates synaptic formation in cultured cortical networks in a dose-dependent manner. Regul. Pept. 2013, 186:43-48.
236. Szentirmai É. Central but not systemic administration of ghrelin induces wakefulness in mice. PLoS One 2012, 7(7):e41172. 10.1371/journal.pone.0041172.
237. Szentirmai E., Krueger J.M. Central administration of neuropeptide Y induces wakefulness in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 291(2):R473-R480.
238. Szentirmai E., Kapás L., Krueger J.M. Ghrelin microinjection into forebrain sites induces wakefulness and feeding in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292(1):R575-R585.
239. Szentirmai E., Kapás L., Sun Y., Smith R.G., Krueger J.M. The preproghrelin gene is required for the normal integration of thermoregulation and sleep in mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(33):14069-14074.
240. Takada M., Campbell K.J., Moriizumi T., Hattori T. On the origin of the dopaminergic innervation of the paraventricular thalamic nucleus. Neurosci Lett. 1990, 115(1):33-36.
241. Takeda S., Matsuzawa T. Age-related brain atrophy: a study with computed tomography. J. Gerontol. 1985, 40(2):159-163.
242. Taylor N., Bramble D. Sleep disturbance and Huntingdon's disease. Br. J. Psychiatry 1997, 171:393.
243. Thompson N.M., Gill D.A., Davies R., Loveridge N., Houston P.A., Robinson I.C., et al. Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of GHS-R1a. Endocrinology 2004, 145(1):234-242.
244. Tong Q., Ye C.P., Jones J.E., Elmquist J.K., Lowell B.B. Synaptic release of GABA by AgRP neurons is required for normal regulation of energy balance. Nat. Neurosci. 2008, 11(9):998-1000.
245. Tóth K., László K., Lénárd L. Role of intraamygdaloid acylated-ghrelin in spatial learning. Brain Res. Bull. 2010, 81(1):33-37.
246. Trejo A., Tarrats R.M., Alonso M.E., Boll M.C., Ochoa A., Velásquez L. Assessment of the nutrition status of patients with Huntington's disease. Nutrition 2004, 20(2):192-196.
247. Tröster A.I., Stalp L.D., Paolo A.M., Fields J.A., Koller W.C. Neuropsychological impairment in Parkinson's disease with and without depression. Arch. Neurol. 1995, 52(12):1164-1169.
248. Tschöp M., Smiley D.L., Heiman M.L. Ghrelin induces adiposity in rodents. Nature 2000, 407(6806):908-913.
249. Tschöp M., Weyer C., Tataranni P.A., Devanarayan V., Ravussin E., Heiman M.L. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001, 50(4):707-709.
250. Unger M.M., Möller J.C., Mankel K., Eggert K.M., Bohne K., Bodden M., et al. Postprandial ghrelin response is reduced in patients with Parkinson's disease and idiopathic REM sleep behaviour disorder: a peripheral biomarker for early Parkinson's disease?. J. Neurol. 2011, 258(6):982-990.
251. Van der Lely A.J. Ghrelin and new metabolic frontiers. Horm. Res. 2009, 71(Suppl. 1):129-133.
252. Vaupel J.W. Biodemography of human ageing. Nature 2010, 464(7288):536-542.
253. Vendette M., Gagnon J.F., Décary A., Massicotte-Marquez J., Postuma R.B., Doyon J., et al. REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia. Neurology 2007, 69(19):1843-1849.
254. Wang L., Saint-Pierre D.H., Taché Y. Peripheral ghrelin selectively increases Fos expression in neuropeptide Y - synthesizing neurons in mouse hypothalamic arcuate nucleus. Neurosci. Lett. 2002, 325(1):47-51.
255. Wang J., Ling S., Usami T., Murata T., Narita K., Higuchi T. Effects of ghrelin, corticotrophin-releasing hormone, and melanotan-II on food intake in rats with paraventricular nucleus lesions. Exp. Clin. Endocrinol. Diabetes 2007, 115(10):669-673.
256. Wang N., Gray M., Lu X.H., Cantle J.P., Holley S.M., Greiner E., et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease. Nat. Med. 2014, 20(5):536-541.
257. Wang X., Wang X.L., Chen H.L., Wu D., Chen J.X., Wang X.X., et al. Ghrelin inhibits doxorubicin cardiotoxicity by inhibiting excessive autophagy through AMPK and p38-MAPK. Biochem. Pharmacol. 2014, 88(3):334-350.
258. Weindruch R., Walford R.L. The Retardation of Aging and Disease by Dietary Restriction 1988, Charles C. Thomas, Springfield, IL.
259. Weintraub D., Comella C.L., Horn S. Parkinson's disease-part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am. J. Manag. Care 2008, 14(2 Suppl.):S40-S48.
260. West M.J., Kawas C.H., Martin L.J., Troncoso J.C. The CA1 region of the human hippocampus is a hot spot in Alzheimer's disease. Ann. N. Y. Acad. Sci. 2000, 908:255-259.
261. Wierup N., Svensson H., Mulder H., Sundler F. The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas. Regul. Pept. 2002, 107(1-3):63-69.
262. Willesen M.G., Kristensen P., Rømer J. Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology 1999, 70(5):306-316.
263. Wu A., Ying Z., Gomez-Pinilla F. The interplay between oxidative stress and brain-derived neurotrophic factor modulates the outcome of a saturated fat diet on synaptic plasticity and cognition. Eur. J. Neurosci. 2004, 19(7):1699-1707.
264. Yagi T., Asakawa A., Ueda H., Miyawaki S., Inui A. The role of ghrelin in patients with functional dyspepsia and its potential clinical relevance. Int. J. Mol. Med. 2013, 32(3):523-531.
265. Yang J., Zhao T.J., Goldstein J.L., Brown M.S. Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(31):10750-10755.
266. Yoshida M., Shirouzu M., Tanaka M., Semba K., Fibiger H.C. Dopaminergic neurons in the nucleus raphe dorsalis innervate the prefrontal cortex in the rat: a combined retrograde tracing and immunohistochemical study using anti-dopamine serum. Brain Res. 1989, 496:373-376.
267. Young D., Lawlor P.A., Leone P., Dragunow M., During M.J. Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective. Nat. Med. 1999, 5(4):448-453.
268. Zafra F., Castrén E., Thoenen H., Lindholm D. Interplay between glutamate and gamma-aminobutyric acid transmitter systems in the physiological regulation of brain-derived neurotrophic factor and nerve growth factor synthesis in hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(22):10037-10041.
269. Zgaljardic D.J., Foldi N.S., Borod J.C. Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions. J. Neural Transm. 2004, 111(10-11):1287-1301.
270. Zhang W., Chai B., Li J.Y., Wang H., Mulholland M.W. Effect of des-acyl ghrelin on adiposity and glucose metabolism. Endocrinology 2008, 149(9):4710-4716.
271. Zhang R., Yang G., Wang Q., Guo F., Wang H. Acylated ghrelin protects hippocampal neurons in pilocarpine-induced seizures of immature rats by inhibiting cell apoptosis. Mol. Biol. Rep. 2013, 40(1):51-58.
272. Zheng H., Corkern M., Stoyanova I., Patterson L.M., Tian R., Berthoud H.R. Peptides that regulate food intake: appetite-inducing accumbens manipulation activates hypothalamic orexin neurons and inhibits POMC neurons. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 284(6):R1436-R1444.
273. Zigman J.M., Jones J.E., Lee C.E., Saper C.B., Elmquist J.K. Expression of ghrelin receptor mRNA in the rat and the mouse brain. J. Comp. Neurol. 2006, 494(3):528-548.